Dr Margeaux Hodgson-Garms observed differences, correct, however, she noted "Moreover, in most assays they are shown to outperform tissue-derived MSC populations, including those derived from bone marrow, which are historically considered the gold standard. Beyond this, iMSC populations demonstrate considerably less inter-population variation than do tissue-derived MSCs, indicating the successful bypass of at least some levels of traditional MSC heterogeneity. This supports the use of iMSC platforms as new source of clinical MSC products. With the potential for large-scale production of more homogeneous, off-the-shelf products, with limited batch-to-batch variation They will likely deliver more predictable, and reproducible, clinical outcomes."
"considerably less" & "more homogeneous"
She came to the conclusion there will still be a difference, but the smaller the differences, the more predictable and reproducable the clinical effect in the target population.
Dr Hodgson-Garms is currently working on the following project, "Using biomaterials to control stem cell metabolism."
"It is possible that changing the mechanical properties of cell culture materials will affect stem cell potential by helping them maintain or recover metabolic function. In this project, the metabolism of mesenchymal stromal cells (MSCs) from different sources (bone marrow, adipose tissue, umbilical cord, and MSCs generated from induced pluripotent stem cells) will be compared using image-based techniques and biochemical assays. The project will also test the effects of culturing the cells on biomaterials with varying mechanical properties (stiff vs soft) and architectures (fibres, pores, micro- and nano-scale structures)." https://www.monash.edu/__data/assets/pdf_file/0006/3360084/SRP-23-24-Margeaux-Hodgson-Garms.pdf
CYP Price at posting:
18.0¢ Sentiment: Hold Disclosure: Held
(20min delay)
